Savient Pharmaceuticals, which launched its gout treatment last year after a decade of efforts, reported a wider net loss and higher revenue in the fourth quarter compared with the same period in 2011.

The East Brunswick-based drugmaker said yesterday it had a quarterly net loss of $30.9 million, or 44 cents per share, compared with a net loss of $0.5 million, or a penny a share, last year. It reported quarterly revenues of $3.7 million, up from $1 million the previous quarter.

The company poured most of its resources into developing Krystexxa, a drug for treating chronic gout in adults who do not respond to other medicines.

“Savient has made great strides in the commercialization of Krystexxa,’’ David Norton, the company’s interium CEO, said in a statement. “We look forward to continuing to build on this momentum to further out position in the marketplace and fill an unmet need for patients suffereing from refractory chronic gout.’’